SYNDAX PHARMACEUTICALS INC

CEO Metzger’s July 8 buy‑sell of 32,375 Syndax shares at $6.38 and $24.24 shows strategic liquidity while keeping long‑term ownership, boosting investor confidence.

Insider trades show Syndax’s confidence as it boosts its AML drug pipeline and raises capital for expansion, offering investors a balanced view of growth risk and strategic potential.

Insider buying spurs confidence in Syndax’s solid‑tumor pipeline, but its negative P/E and recent price dip caution investors to weigh long‑term prospects.

Insider buying at Syndax Pharmaceuticals shows strong confidence in growth; insiders like Jennifer Jarrett and CEO Michael Metzger are buying RSUs, hinting at potential upside for investors.

Insider buying spree at Syndax Pharmaceuticals signals confidence in its oncology pipeline; insiders, including Huber Martin Jr., are buying low‑cost RSUs and shares, suggesting long‑term upside potential and a vote of confidence for investors.

Insider buying spurs confidence in Syndax Pharmaceuticals, highlighting its solid‑tumor immunotherapy pipeline, commercial strategy, and late‑stage trial prospects.